Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Patricia Stow(St. Jude Children's Research Hospital), Dario Campana(National University of Singapore), Elaine Coustan‐Smith(St. Jude Children's Research Hospital), Yinmei Zhou(St. Jude Children's Research Hospital), Charles G. Mullighan(St. Jude Children's Research Hospital), Geoffrey Neale(St. Jude Children's Research Hospital), Xiaohua Chen, Qiulu Pan, Laura Key, Ching‐Hon Pui(St. Jude Children's Research Hospital)
Cited by 159
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
|Cancer Cell|2002|1.9k
HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells
|The Journal of Experimental Medicine|2011|1.8k